{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant to ZoneOne Pharma, Inc., of an exclusive evaluation option license to practice the inventions embodied in the following US Patent (and all foreign counterparts): Serial No. 6,890,917 entitled, \"Geldanamycin Derivative and Method of Treating Cancer Using Same\" [HHS Ref. E-050-2000/0-US- 15]. The patent rights in this invention have been assigned to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide, and the field of use may be limited to:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/03/18/2013-06069.html","cfr_references":[],"citation":"78 FR 16692","comment_url":null,"comments_close_on":"2013-04-02","correction_of":null,"corrections":[],"dates":"Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before April 2, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-06069","effective_on":null,"end_page":16692,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/03/18/2013-06069.xml","html_url":"https://www.federalregister.gov/documents/2013/03/18/2013-06069/prospective-grant-of-start-up-option-exclusive-license-the-development-of-liposomal-therapeutic","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-06069?publication_date=2013-03-18","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-03-18/2013-06069/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":59,"last_updated":"2026-08-25 08:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-03-18/pdf/2013-06069.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-06069.pdf?1363352076","publication_date":"2013-03-18","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/03/18/2013-06069.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-04-07T06:00:13Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":16692,"subtype":null,"title":"Prospective Grant of Start-Up Option Exclusive License: The Development of Liposomal Therapeutic Agents for the Treatment of Human Epithelial Cancers and Liposarcomas","toc_doc":"Development of Liposomal Therapeutic Agents for Treatment of Human Epithelial Cancers and Liposarcomas","toc_subject":"Start-Up Option Exclusive License:","topics":[],"type":"Notice","volume":78}